Non-coding RNA Trojan nanocarriers in CRC: Mechanistic crossroads and therapeutic challenges

Area of Science:

• Oncology
• Nanomedicine
• Molecular Biology

Background:

• Colorectal cancer (CRC) chemoresistance is a major clinical challenge, driven by cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT).
• Non-coding RNAs (ncRNAs) are key regulators in CRC chemoresistance, presenting therapeutic targets.
• Effective delivery of ncRNAs remains a significant hurdle for clinical application.

Purpose of the Study:

• To review the role of ncRNAs in CRC chemoresistance.
• To elaborate on the design and efficacy of a nanoscale
• Trojan Horse
• drug delivery system for ncRNA-based therapies.
• To highlight the potential of this system in overcoming CRC cross-resistance.

Main Methods:

• Systematic review of ncRNA-mediated regulation in CRC chemoresistance.
• Detailed analysis of the triple-targeting strategy of the nanoscale
• Trojan Horse
• system (tissue, cellular, molecular levels).
• Exploration of synergistic combination therapies and theranostic capabilities.

Main Results:

• The
• Trojan Horse
• system demonstrates precise delivery to CSCs and chemoresistant cells.
• It effectively targets stemness, EMT, and chemoresistance pathways.
• The system facilitates multi-modal combination therapies and integrates theranostic functions.

Conclusions:

• The nanoscale
• Trojan Horse
• drug delivery system offers a promising strategy for overcoming ncRNA-mediated CRC chemoresistance.
• This approach has the potential to advance the clinical translation of ncRNA nanotherapies.
• Integrating synergistic treatments and theranostics enhances therapeutic efficacy and monitoring.